Sign Up Today and Learn More About NewLimit Stock
Invest in or calculate the value of your shares in NewLimit or other pre-IPO companies through EquityZen, part of Morgan Stanley.
NewLimit Stock (NEWM)
NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.
About NewLimit Stock
Founded
2022
Headquarters
South San Francisco, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
NewLimit Press Mentions
Stay in the know about the latest news on NewLimit
The US loves longevity. Can Europe turn it into venture category
vestbee • Sep 24, 2026
Investors pour over $30bn into longevity biotech as report predicts longevity drugs from 2035
prnewswire • Sep 16, 2026
Anti-Aging Drugs Market Poised for US$ 102.5 Bn Valuation by 2031, Growing at 6.25% CAGR, New Report by Wissen Research
prnewswire • Sep 05, 2026
Anti-Aging Drugs Market Poised for US$ 102.5 Bn Valuation by 2031, Growing at 6.25% CAGR, New Report by Wissen Research
prnewswire • Sep 04, 2026
Biotech Startup Investment Held Steady Even As AI Funding Surged
news • Aug 31, 2026
NewLimit Management
Leadership team at NewLimit
Co-Founder & Head of Machine Learning
Greg Johnson
Co-founder & Head of Research
Jacob Kimmel
Join now and verify your accreditation status to gain access to:
- NewLimit Current Valuation
- NewLimit Stock Price
- NewLimit Management
- Available deals in NewLimit and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- NewLimit Cap Table and Funding History by Share Class and Liquidity Preferences
- NewLimit Revenue and Financials
- NewLimit Highlights
- NewLimit Business Model
- NewLimit Risk Factors
- NewLimit Research Report from SACRA Research
Trading NewLimit Stock
How to invest in NewLimit stock?
Accredited investors can buy pre-IPO stock in companies like NewLimit through EquityZen funds. These investments are made available by existing NewLimit shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell NewLimit stock?
Shareholders can sell their NewLimit stock through EquityZen's private company marketplace. EquityZen's network includes over 480K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 56K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
